The estimated Net Worth of Karah Herdman Parschauer is at least $9.81 Milhão dollars as of 12 June 2024. Ms. Parschauer owns over 9,806 units of Ultragenyx Pharmaceutical stock worth over $3,266,070 and over the last 8 years she sold RARE stock worth over $4,507,090. In addition, she makes $2,036,330 as Executive Vice President e General Counsel at Ultragenyx Pharmaceutical.
Karah has made over 25 trades of the Ultragenyx Pharmaceutical stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 9,806 units of RARE stock worth $441,270 on 12 June 2024.
The largest trade she's ever made was selling 12,370 units of Ultragenyx Pharmaceutical stock on 17 August 2020 worth over $1,093,879. On average, Karah trades about 2,461 units every 45 days since 2016. As of 12 June 2024 she still owns at least 57,981 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Ms. Parschauer stock trades at the bottom of the page.
Karah Parschauer J.D. serves as Executive Vice President, General Counsel of the Company. Prior to Ultragenyx, Ms. Parschauer served in various executive capacities, and most recently as Vice President, Associate General Counsel, at Allergan plc, a pharmaceutical company, from June 2005 until June 2016. Prior to Allergan, Ms. Parschauer was an attorney at Latham & Watkins LLP, where she practiced in the areas of mergers and acquisitions, securities offerings and corporate governance. Ms. Parschauer has served on the board of directors of Arcturus Therapeutics, Ltd., a publicly traded RNA medicines company, since June 2019 and on the board of directors of Evolus, Inc., a publicly traded performance beauty company, since July 2019. Ms. Parschauer holds a B.A. in Biology from Miami University and a J.D. from Harvard Law School.
As the Executive Vice President e General Counsel of Ultragenyx Pharmaceutical, the total compensation of Karah Parschauer at Ultragenyx Pharmaceutical is $2,036,330. There are 5 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
Karah Parschauer is 42, she's been the Executive Vice President e General Counsel of Ultragenyx Pharmaceutical since 2016. There are 25 older and no younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Karah's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr, eClay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: